This is a milestone for the globalization of drug approval 

On September 17, 2019, the U.S. Food and Drug Administration (FDA), the Therapeutic Products Administration of Australia (TGA), and Health Canada announced the fast-track approval of Lenvima (Lenvatinib) in combination with Keytruda (Pembrolizumab). Drug K (hereinafter referred to as drug K) is used for the treatment of advanced endometrial cancer, which is not accompanied by MSI-H and does not carry mismatch damage repair defect (dMMR) in patients whose disease progression is not suitable for surgery or radiotherapy after systematic treatment. This is the United States FDA since the establishment of oncology Center of Excellence (OCE) in 2017, launched the first Orbis program results, the realization of drug approval globalization and cancer "moon shot plan" practice has a milestone significance.

On September 17, 2019, the U.S. Food and Drug Administration (FDA), the Therapeutic Products Administration of Australia (TGA), and Health Canada announced the fast-track approval of Lenvima (Lenvatinib) in combination with Keytruda (Pembrolizumab). Drug K (hereinafter referred to as drug K) is used for the treatment of advanced endometrial cancer, which is not accompanied by MSI-H and does not carry mismatch damage repair defect (dMMR) in patients whose disease progression is not suitable for surgery or radiotherapy after systematic treatment. This is the United States FDA since the establishment of oncology Center of Excellence (OCE) in 2017, launched the first Orbis program results, the realization of drug approval globalization and cancer "moon shot plan" practice has a milestone significance.

Jenner's work is highly recognized  

On September 17, 2019, the U.S. Food and Drug Administration (FDA), the Therapeutic Products Administration of Australia (TGA), and Health Canada announced the fast-track approval of Lenvima (Lenvatinib) in combination with Keytruda (Pembrolizumab). Drug K (hereinafter referred to as drug K) is used for the treatment of advanced endometrial cancer, which is not accompanied by MSI-H and does not carry mismatch damage repair defect (dMMR) in patients whose disease progression is not suitable for surgery or radiotherapy after systematic treatment. This is the United States FDA since the establishment of oncology Center of Excellence (OCE) in 2017, launched the first Orbis program results, the realization of drug approval globalization and cancer "moon shot plan" practice has a milestone significance.

On September 17, 2019, the U.S. Food and Drug Administration (FDA), the Therapeutic Products Administration of Australia (TGA), and Health Canada announced the fast-track approval of Lenvima (Lenvatinib) in combination with Keytruda (Pembrolizumab). Drug K (hereinafter referred to as drug K) is used for the treatment of advanced endometrial cancer, which is not accompanied by MSI-H and does not carry mismatch damage repair defect (dMMR) in patients whose disease progression is not suitable for surgery or radiotherapy after systematic treatment. This is the United States FDA since the establishment of oncology Center of Excellence (OCE) in 2017, launched the first Orbis program results, the realization of drug approval globalization and cancer "moon shot plan" practice has a milestone significance.

On September 17, 2019, the U.S. Food and Drug Administration (FDA), the Therapeutic Products Administration of Australia (TGA), and Health Canada announced the fast-track approval of Lenvima (Lenvatinib) in combination with Keytruda (Pembrolizumab). Drug K (hereinafter referred to as drug K) is used for the treatment of advanced endometrial cancer, which is not accompanied by MSI-H and does not carry mismatch damage repair defect (dMMR) in patients whose disease progression is not suitable for surgery or radiotherapy after systematic treatment. This is the United States FDA since the establishment of oncology Center of Excellence (OCE) in 2017, launched the first Orbis program results, the realization of drug approval globalization and cancer "moon shot plan" practice has a milestone significance.

On September 17, 2019, the U.S. Food and Drug Administration (FDA), the Therapeutic Products Administration of Australia (TGA), and Health Canada announced the fast-track approval of Lenvima (Lenvatinib) in combination with Keytruda (Pembrolizumab). Drug K (hereinafter referred to as drug K) is used for the treatment of advanced endometrial cancer, which is not accompanied by MSI-H and does not carry mismatch damage repair defect (dMMR) in patients whose disease progression is not suitable for surgery or radiotherapy after systematic treatment. This is the United States FDA since the establishment of oncology Center of Excellence (OCE) in 2017, launched the first Orbis program results, the realization of drug approval globalization and cancer "moon shot plan" practice has a milestone significance.